Use of a High-Throughput Genotyping Platform (OncoMap) for <i>RAS</i> Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer

Published:2017-01-15 Issue:1 Volume:49 Page:37-43
ISSN:1598-2998
Container-title:Cancer Research and Treatment
language:en
Short-container-title:Cancer Res Treat

Author:

Kim Dalyong,Hong Yong Sang,Kim Jeong Eun,Kim Kyu-pyo,Lee Jae-Lyun,Chun Sung-Min,Kim Jihun,Jang Se Jin,Kim Tae Won

Funder

Ministry of Health and Welfare and Family Affairs

Ministry of Health and Welfare

Asan Institute for Life Sciences, Asan Medical Center

Publisher

Korean Cancer Association

Subject

Cancer Research,Oncology

Link

http://e-crt.org/upload/pdf/crt-2016-069.pdf

Reference19 articles.

1. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012

2. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

3. Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

4. Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia

5. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metastatik Kolorektal Kanserli Hastaların RAS Mutasyon Durumuna Göre Klinik Ve Patolojik Özellikleri;Uludağ Üniversitesi Tıp Fakültesi Dergisi;2019-08-01

2. Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer;Cancer Research and Treatment;2018-10-15

3. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS;Annals of Oncology;2018-01

4. Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer;BMC Gastroenterology;2017-11-23